Home › Guides › How to trade FDA decisions in biotech: binary events, survivable size

Binary catalysts

How to trade FDA decisions in biotech: binary events, survivable size

Trading an FDA decision means betting on a binary event: on the PDUFA date or a pivotal readout the stock usually gaps 30-80% one direction with almost no middle ground. This guide covers what these catalysts are, why they behave like lottery tickets, how IV crush can beat you even when you're right, and how to size a position so a total loss is survivable. Research and education only — not financial advice.

The short answer

An FDA decision — a PDUFA approval date, a pivotal Phase 3 readout, or an advisory-committee vote — is a binary catalyst: on the release the stock typically gaps 30-80% one way or the other, with no gentle middle outcome. There is no way to "trade the chart" through one, because the price on the other side is set by a yes/no result you cannot handicap. The only durable way to hold a position into one is to size it so a total loss is an amount you planned to lose. You are buying a coin flip on a stapled-on payout, not a setup with a trigger and a stop you can honor.

This is the hardest catalyst to trade in the market. Unlike an earnings report, where guidance and history give you a distribution, a drug approval is closer to a switch: it flips, and the stock re-rates in seconds. Treat any single trade as capital you can afford to zero.

What a binary biotech catalyst actually is

A handful of scheduled and semi-scheduled events drive these moves:

PDUFA date — the deadline by which the FDA must act on a new-drug application. The agency either approves, issues a Complete Response Letter (CRL) rejecting or delaying it, or occasionally extends. For a small company whose valuation rides on one drug, approval and a CRL can be a two- to five-fold difference in the stock.
Phase 3 topline readout — the pivotal trial result. "Met its primary endpoint" versus "missed" is the whole ballgame; a miss on a single-asset biotech can erase 60-90% of the market cap in one print.
Advisory committee (AdCom) — an outside panel votes to recommend for or against approval. The FDA isn't bound by it, but the vote itself gaps the stock, and briefing documents released two days prior can gap it again.

The common thread: the outcome is discontinuous, the timing is roughly known, and the entire market is watching the same date. That combination is exactly what makes the options expensive.

Why these trade like lottery tickets

Because everyone can see the date, the option market prices the fear in advance. Implied volatility on a biotech into a PDUFA can run several times its normal level — the market is quoting a huge expected move, and you pay for all of it in the premium. Two things follow, and both work against a naive buyer.

First, the break-evens are brutal. If a $12 stock has to move to $18 just for your calls to break even, you don't need to be right about approval — you need to be right about approval and the size of the pop clearing an already-inflated bar. Second, and more punishing, is IV crush: the instant the result is public, uncertainty collapses and implied volatility deflates violently. A call can be directionally correct — the drug is approved, the stock gaps up — and still lose money, because the volatility you overpaid for evaporates faster than the move pays you. This is the signature trap of catalyst options and the reason "I was right and still lost" is a biotech cliché.

Being right on direction is necessary but not sufficient. On a binary event you must beat the implied move and survive the volatility collapse that follows it.

The two-sided gap, in numbers

Consider a hypothetical single-asset biotech trading at $10 the day before a PDUFA. The at-the-money options imply roughly a ±55% move. Two outcomes dominate:

Outcome	Typical gap	Stock next open
Approval / endpoint met	+50% to +80%	~$15-$18
CRL / endpoint missed	-50% to -75%	~$2.50-$5

Notice what's missing: a $9-to-$11 outcome. The middle is nearly empty, which is why a stop-loss is close to useless here — the stock leaps over your stop overnight and fills far below it. You do not get to "cut it at -20%." You are effectively all-in on the binary the moment you hold through the release. That is the definition of a lottery ticket: a small, defined cost for a large, uncertain, discontinuous payout.

The only rule that matters: survivable size

If you choose to take one of these — as a small, speculative flyer, fully aware it can zero — the discipline lives entirely in position sizing, not entry timing. The premise is that any single ticket may be a complete loss, so the bet is capped at an amount that a zero won't dent.

Worked example

Set the risk budget first. On a $5,000 account, a strict catalyst cap might be 1% per binary event = $50 — far tighter than a normal 10% options rule, because the loss probability is genuinely high and the stop won't save you.
Let the budget set the quantity. If the pre-event calls cost $1.20 ($120 per contract), $50 doesn't even buy one contract — the honest answer is to pass or trade a smaller-priced structure, not to stretch the budget to "make it fit."
Assume zero, not the moon. Size as if the outcome is a CRL and the position goes to $0. If that dollar figure would change how you sleep, it's too big.
Never average down into the event. Adding on a pre-release dip concentrates a single binary — it turns one lottery ticket into three of the same ticket.

Run these numbers yourself before committing capital: our free position size calculator turns an account balance and a max-risk percentage into a dollar cap, and the risk-reward calculator shows how far the stock must gap just to clear an inflated premium. The math, not the story, decides whether the trade is even worth taking.

Defined-risk structures exist, but they're not free lunches. Some traders express a binary view with spreads to cap cost and dampen IV crush, or a straddle/strangle to bet on magnitude rather than direction. Each has its own trap: spreads cap the upside you came for, and a straddle can still lose if the realized move is smaller than the enormous move the premium already priced in. There is no structure that removes the binary — only ones that reshape where you can be wrong.

How our desk treats catalysts like this

Most FDA binaries never become a published card, because a setup you can't define a stop on fails our process by default. Our workflow — full-market scan, catalyst check, adversarial review, liquidity screen — only produces a trigger-based card when there is an entry, targets, a stop, and a time-stop we could post before the move. A pure coin-flip has none of those, so it usually gets flagged as an event to avoid sizing into, not a trade to chase. For scale on why process outranks any single call: our published hypothetical backtest of the raw scanner logged a 46.6% simulated win rate and a 0.82 simulated profit factor across 161 hypothetical trades — a reminder that even a disciplined system loses without sizing rules on top. Every card, winners and losers alike, stays up on the public record, and the trigger-based format is shown on the signals page.

The 30-second recap

FDA decisions (PDUFA, Phase 3, AdCom) are binary: expect a 30-80% gap one way, with almost no middle outcome.
Options are priced for the fear in advance — high IV means brutal break-evens and violent IV crush after the print.
You can be right on direction and still lose, because the volatility you paid for collapses on the news.
A stop-loss won't protect you — the stock gaps over it overnight. Size as if the position can go to zero.
Discipline is entirely in the size, not the entry: cap the bet at money you planned to lose, and never average down into the event.

Common questions

How do you trade an FDA decision like a PDUFA date?

You treat it as a binary bet, not a chartable setup. On the decision the stock typically gaps 30-80% one direction with no middle outcome, so a stop-loss can't protect you — the gap jumps over it. The practical approach is to decide in advance whether you're taking a small, defined-risk speculative position, size it as if it can go to zero (often just 1% of the account or less), and accept that direction alone doesn't guarantee a profit because of IV crush. Many traders and desks simply avoid sizing into pure binaries.

Why can I lose money on a biotech call even if the drug is approved?

Because of IV crush. Going into a PDUFA or Phase 3 readout, implied volatility is inflated as the market prices a huge expected move, and you pay for all of it in the premium. When the result is public, uncertainty collapses and IV deflates violently. If the actual stock move is smaller than the enormous move already baked into the option, the volatility you overpaid for evaporates faster than the price gain pays you — so a directionally correct call can still lose.

How much should I risk on a binary biotech catalyst?

There's no universal number, but the governing principle is that any single ticket can be a total loss, so cap it at an amount that a zero won't hurt. Some traders use a much tighter limit than their normal options rule — for example 1% of the account per binary event rather than 10% — precisely because the loss probability is high and a stop won't save you. Size from a fixed dollar risk budget, assume the position goes to zero, and never average down into the event. This is a risk-control convention, not a promise about outcomes.

Are FDA catalyst trades worth it?

They are among the hardest trades in the market because the outcome is discontinuous and the options are expensive relative to the move. For most accounts they function as small speculative flyers rather than a repeatable edge — the expensive premium, the two-sided gap, and IV crush stack the odds against a naive buyer. If you take them at all, the honest framing is a capped-cost lottery ticket you've sized to survive, not a strategy you scale into.

See the process with your own eyes. The desk posts trigger-based cards to a public, timestamped record — losses included — and published the backtest where its own raw scanner loses. The scoreboard is free to watch. Join the floor →

Free to join · paid floors optional · research and education only

Last updated 2026-07-11 · ClaudeQuantAlgo Research Desk · research and education only.

Disclosures. ClaudeQuantAlgo is a research and education community. Nothing on this page constitutes financial, investment, legal, or tax advice, or a recommendation to buy or sell any security or derivative. No profit promises are made, ever — trading stocks, options, and forex involves substantial risk of loss; options positions can lose 100% of their value. The public scoreboard reflects a model ("paper") desk — no real money. Past performance — real, paper, or simulated — never guarantees future results. Hypothetical and simulated results have inherent limitations and no representation is made that any account will or is likely to achieve similar profits or losses. ClaudeQuantAlgo is not a registered investment adviser or broker-dealer. You are solely responsible for your own trading decisions. Never risk money you cannot afford to lose.